Moderna, Inc. (MRNA)

Moderna's stock has shown significant volatility but has rebounded strongly, increasing by approximately 101.44% over the last year. Key events include Q1 2026 earnings surpassing expectations due to international COVID-19 vaccine sales, regulatory setbacks and reversals for its flu vaccine, positive Phase 3 flu vaccine data, European approvals for multiple vaccines, and a litigation settlement impacting net loss.

Demand seasonality for Moderna's products is becoming increasingly relevant as the company shifts to a broader adult respiratory vaccine company. While COVID-19 vaccine demand is now more seasonal, Moderna anticipates seasonal demand for its respiratory products, with a focus on building a commercial respiratory franchise.

Moderna, Inc. is a biotechnology company focused on mRNA technology-based therapeutics and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna aims to create transformative medicines using its proprietary mRNA platform. The company's core business segments include vaccines, therapeutics, and platform technologies, with key products like Spikevax (COVID-19 Vaccine) and mRESVIA (RSV Vaccine).

Moderna's headquarters is in Cambridge, Massachusetts, and it has a commercial presence in 11 countries. The company plans to expand to ten additional markets in Asia-Pacific and Europe. Moderna has commercial agreements with distributors in 45 countries and manufacturing facilities in the United States and Europe, including new facilities in the UK and Canada.

Moderna's brand reputation has been influenced by its pioneering work in mRNA technology and rapid development of the COVID-19 vaccine. However, it has faced scrutiny over vaccine pricing, patent disputes (including a lawsuit by GSK plc), and regulatory scrutiny of mRNA technology, particularly in the U.S.

Moderna's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion (approximately 75.33%), with major holders including The Vanguard Group, Inc. and BlackRock, Inc. Insiders hold approximately 7.73% of the stock, with recent trading activity showing more sales than purchases.